Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacopo De Cristofaro

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Cureus|September 30, 2024
Edoxaban-Induced Vanishing Bile Duct Syndrome: A Case Report With Review of the LiteratureElisa Borgonovo, Jacopo De Cristofaro, Federico Aletti, et al.
JACC. Case Reports|February 16, 2024
Cat Scratch EndocarditisJacopo De Cristofaro, Stefania Sacchi, Luca Baldetti, et al.
Microorganisms|July 2, 2021
Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center ExperienceArta Karruli, Jacopo de Cristofaro, Roberto Andini, et al.
Journal of Hepatology|February 28, 2026
Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)Sherrie Bhoori, Licia Rivoltini, David J Pinato, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Cureus|September 30, 2024
Edoxaban-Induced Vanishing Bile Duct Syndrome: A Case Report With Review of the LiteratureElisa Borgonovo, Jacopo De Cristofaro, Federico Aletti, et al.
JACC. Case Reports|February 16, 2024
Cat Scratch EndocarditisJacopo De Cristofaro, Stefania Sacchi, Luca Baldetti, et al.
Microorganisms|July 2, 2021
Risk Factors and Outcome of Multidrug-Resistant Infections after Heart Transplant: A Contemporary Single Center ExperienceArta Karruli, Jacopo de Cristofaro, Roberto Andini, et al.
Journal of Hepatology|February 28, 2026
Efficacy of liver transplantation after response to atezolizumab-bevacizumab downstaging of intermediate and advanced hepatocellular carcinoma (ImmunoXXL)Sherrie Bhoori, Licia Rivoltini, David J Pinato, et al.
Pageof 1